[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dendritic-cell\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dendritic-cell":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100439257","phase-1-hypomemylating-agents-combination-with-edc-therapy-for-elderly-patients-with-myelodysplastic-syndrome-100439257",false,"NCT04999943","Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome","A Randomized, Open-label, Clinical Trial to Compare the Safety and Efficacy of Hypomemylating Agents Monotherapy and Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome","eDC-MDS","Inclusion Criteria:\n\n1. elderly MDS patients;\n2. aged more than 60 years old, general condition, ECOG score less than 1;\n3. normal function of heart, liver and kidney, serum bilirubin ≤ 35 umol \u002F L; serum creatinine ≤ 150 umol \u002F L;\n4. patients are unsuitable or unwilling to receive hematopoietic stem cell transplantation;\n5. subjects sign informed consent.\n\nExclusion criteria:\n\n1. serious infection was not controlled before treatment;\n2. contraindications for the use of dexitabine and azacytidine;\n3. other cases that did not meet the admission criteria.","ALL","60 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The purpose of this study is to optimize the traditional treatment scheme and explore the cure scheme for the elderly by combining the existing mature treatment technology. The primary aim of this innovative immunotherapy using WT1\u002FhTERT\u002FSurvivin-loaded DCs is to determine whether this novel DC vaccination is safe and can significantly prevent clinical relapse and increase survival of MDS patients.",[27,28,29,30],"Myelodysplastic Syndromes","Dendritic Cell","Hypomethylating Agents","Immunotherapy","RECRUITING","2021-08-10",{"date":34,"type":35},"2021-08-11","ACTUAL",{"date":37,"type":35},"2021-07-01",{"date":39,"type":21},"2026-07-01",{"name":41,"class":42},"Affiliated Hospital to Academy of Military Medical Sciences","OTHER"]